Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
07. August 2023 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and...